CLINICAL STAGE-1 NON-HODGKINS-LYMPHOMA - LONG-TERM FOLLOW-UP OF PATIENTS TREATED BY THE BRITISH NATIONAL LYMPHOMA INVESTIGATION WITH RADIOTHERAPY ALONE AS INITIAL THERAPY

被引:121
作者
HUDSON, BV
HUDSON, GV
MACLENNAN, KA
ANDERSON, L
LINCH, DC
机构
[1] UCL, SCH MED, DEPT HAEMATOL, BRITISH NATL LYMPHOMA INVEST, LONDON W1N 8AA, ENGLAND
[2] UCL, SCH MED, DEPT ONCOL, BRITISH NATL LYMPHOMA INVEST, LONDON W1N 8AA, ENGLAND
[3] ST JAMESS UNIV HOSP, INST CANC STUDIES, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND
关键词
D O I
10.1038/bjc.1994.213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis was performed of 451 adult patients with clinical stage 1/1E non-Hodgkin's lymphoma treated initially with radiotherapy alone. Histopathologically 208 patients had low-grade disease and 243 patients high-grade disease. The complete remission (CR) rate was higher in patients with low-grade disease (98%) than in those with high-grade disease (84%) (P<0.0001). The relapse rate was similar in both histological categories, and relapse usually occurred within 5 years. The resulting overall actuarial percentage of patients achieving CR and remaining disease free (at 10 years) was 47% in patients with low-grade disease and 45% for those with high-grade disease. Salvage therapy was frequently successful in younger patients, and the overall cause-specific survival at 10 years was 71% for low-grade disease and 67% for high-grade disease. In those patients under 60 years of age at diagnosis, the overall cause-specific survival at 10 years was 84% and 80% for those with low-grade and high-grade disease respectively. These long-term results in young patients with clinical stage 1 disease are encouraging, and it will be difficult to demonstrate improved survival with initial chemotherapy either with or without radiotherapy, until new prognostic factors are found to identify poor-risk patients.
引用
收藏
页码:1088 / 1093
页数:6
相关论文
共 26 条
[11]   TREATMENT OF LOCALIZED AGGRESSIVE LYMPHOMAS WITH COMBINATION CHEMOTHERAPY FOLLOWED BY INVOLVED-FIELD RADIATION-THERAPY [J].
LONGO, DL ;
GLATSTEIN, E ;
DUFFEY, PL ;
IHDE, DC ;
HUBBARD, SM ;
FISHER, RI ;
JAFFE, ES ;
GILLIOM, M ;
YOUNG, RC ;
DEVITA, VT .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1295-1302
[12]  
MILLER TP, 1980, CANCER CHEMOTH PHARM, V4, P67
[13]   PRIMARY GASTROINTESTINAL NON-HODGKIN LYMPHOMA - A REVIEW OF 175 BRITISH NATIONAL LYMPHOMA INVESTIGATION CASES [J].
MORTON, JE ;
LEYLAND, MJ ;
HUDSON, GV ;
HUDSON, BV ;
ANDERSON, L ;
BENNETT, MH ;
MACLENNAN, KA .
BRITISH JOURNAL OF CANCER, 1993, 67 (04) :776-782
[14]  
NISSEN NI, 1983, CANCER, V52, P1, DOI 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO
[15]  
2-M
[16]  
NISSEN NI, 1985, LEUKAEMIA LYMPHOMAS, P97
[17]  
OREILLY S, 1990, 4 INT C MAL LYMPH
[18]   CURRENT ISSUES IN CANCER .8. NON-HODGKINS-LYMPHOMA .1. CHARACTERIZATION AND TREATMENT [J].
OREILLY, SE ;
CONNORS, JM .
BRITISH MEDICAL JOURNAL, 1992, 304 (6843) :1682-1686
[19]  
PARYANI SB, 1983, CANCER-AM CANCER SOC, V52, P2300, DOI 10.1002/1097-0142(19831215)52:12<2300::AID-CNCR2820521224>3.0.CO
[20]  
2-Y